Blockade of the bradykinin B(2) receptor provides therapeutic benefit in hereditary angioedema (HAE) and potentially in many other diseases. In a recent study published in the Journal of Medicinal Chemistry, Gibson and his coleagues from the Department of Medicinal Chemistry, Jerini AG, Berlin, Germany, describe the development of highly potent B(2) receptor antagonists with a molecular weight of approximately 500 g/mol.
Source: PMID: 19552431 / J Med Chem. 2009 Jul 23;52(14):4370-9.
Last update: 08.25.2009